Despite geographical and seasonal variations,3, 4 the generally agreed incidence of Bell's palsy is 15–30 cases each year per 100 000 population. Ozonoff and colleagues2
rightly state that the predicted 12-month (annual) incidence of Bell's palsy inferred from mRNA vaccine trials is higher than that reported during the 2-month observation period of these studies. They concluded that the observed incidence of Bell's palsy in the mRNA vaccine arms was 3·5 to seven times higher than expected in the general population. However, safety data were collected for participants with a median follow-up of 2 months after the second dose; therefore, the data refer to an overall observation period of approximately 12 weeks from dose one. Given this, and considering Bell's palsy as the possible outcome of individual doses, the observed incidence in the mRNA vaccine trials would be roughly 1·5 to three times higher than in the general population.
Bell's palsy and SARS-CoV-2 vaccines—an unfolding story - The Lancet Infectious Diseases
I only happened upon this because of personal interest. A vaccinated friend of mine developed Bell's palsy recently. He had the Pfizer vaccine.
It's a non-lethal and treatable malady, but one that is not yet officially acknowledged as a side effect, despite a) having been observed in trials (the assessment of those trials was that it was within the normal rates of occurrence within the general population, although in every trial instance, there were more reported occurrences within the vaccine group than the placebo group) and b) the study cited above.
rightly state that the predicted 12-month (annual) incidence of Bell's palsy inferred from mRNA vaccine trials is higher than that reported during the 2-month observation period of these studies. They concluded that the observed incidence of Bell's palsy in the mRNA vaccine arms was 3·5 to seven times higher than expected in the general population. However, safety data were collected for participants with a median follow-up of 2 months after the second dose; therefore, the data refer to an overall observation period of approximately 12 weeks from dose one. Given this, and considering Bell's palsy as the possible outcome of individual doses, the observed incidence in the mRNA vaccine trials would be roughly 1·5 to three times higher than in the general population.
Bell's palsy and SARS-CoV-2 vaccines—an unfolding story - The Lancet Infectious Diseases
I only happened upon this because of personal interest. A vaccinated friend of mine developed Bell's palsy recently. He had the Pfizer vaccine.
It's a non-lethal and treatable malady, but one that is not yet officially acknowledged as a side effect, despite a) having been observed in trials (the assessment of those trials was that it was within the normal rates of occurrence within the general population, although in every trial instance, there were more reported occurrences within the vaccine group than the placebo group) and b) the study cited above.